The upcoming The FLORetina International Congress on OCT Angiography, En Face OCT, and Advances in OCT (FLORetina-ICOOR) in Florence, Italy, is hosting 57 exhibitors who will showcase their latest ...
Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO shape individualized therapeutic goals and the use of newer anti-VEGF agents.
Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO shape individualized therapeutic goals and the use of newer anti-VEGF agents.
Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific insights—guide tailored treatment strategies for BRVO, CRVO, and DME. This ...
RUSH2A is an ongoing natural history study for patients with mutations in the USH2A gene causing Usher syndrome type 2A or nonsyndromic retinitis pigmentosa (RP). The Foundation Fighting Blindness has ...
Best disease, also known as vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and ...
Anat Loewenstein, MD, discusses the transformative impact of home OCT and AI on monitoring retinal diseases at AAO 2025. During the American Academy of Ophthalmology (AAO) 2025 annual meeting, the Eye ...
Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of Ophthalmology Times for more than 20 ...
New five-year data reveals SYFOVRE significantly delays geographic atrophy progression, enhancing understanding of age-related macular degeneration treatment. Apellis Pharmaceuticals recently ...
Research on aflibercept 8 mg reveals promising real-world outcomes for treating wet AMD and diabetic macular edema, enhancing vision and safety. Diana Do, MD, professor of ophthalmology and vice chair ...
This resubmission follows the complete response letter (CRL) Outlook received in August 2025. The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) ...
A panelist discusses how evolving imaging and the approval of NT-501 therapy are transforming macular telangiectasia type 2 from a diagnostic challenge into a treatable condition. A panelist discusses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback